Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + rosuvastatin
- Development stage
- Phase 3
- Lead developer
- CMG Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CMG190303 is a fixed-dose combination small molecule therapeutic being developed by CMG Pharmaceutical for the management of type 2 diabetes mellitus and comorbid dyslipidemia. The product combines dapagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, with rosuvastatin calcium, an HMG-CoA reductase inhibitor (statin). Dapagliflozin functions by reversibly inhibiting SGLT-2 in the renal proximal convoluted tubule, which reduces glucose reabsorption and increases urinary glucose excretion to lower blood sugar levels. Rosuvastatin addresses dyslipidemia by inhibiting the rate-limiting enzyme in hepatic cholesterol synthesis, thereby reducing LDL cholesterol levels. This dual-action approach is designed to improve both glycemic control and lipid management in patients at risk for cardiovascular disease. CMG190303 is currently being evaluated in multicenter Phase III clinical trials.
- Brand names
- CMG190303CMG-190303CMG 190303
- Other names
- dapagliflozin/rosuvastatindapagliflozin/rosuvastatin calcium
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on dapagliflozin + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + rosuvastatin.